Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia


Amyotrophic lateral sclerosis (ALS) is a paralytic and usually fatal disorder caused by motor-neuron degeneration in the brain and spinal cord. Most cases of ALS are sporadic but about 5–10% are familial. Mutations in superoxide dismutase 1 (SOD1)1,2, TAR DNA-binding protein (TARDBP, also known as TDP43)3,4 and fused in sarcoma (FUS, also known as translocated in liposarcoma (TLS))5,6 account for approximately 30% of classic familial ALS. Mutations in several other genes have also been reported as rare causes of ALS or ALS-like syndromes7,8,9,10,11,12,13,14,15. The causes of the remaining cases of familial ALS and of the vast majority of sporadic ALS are unknown. Despite extensive studies of previously identified ALS-causing genes, the pathogenic mechanism underlying motor-neuron degeneration in ALS remains largely obscure. Dementia, usually of the frontotemporal lobar type, may occur in some ALS cases. It is unclear whether ALS and dementia share common aetiology and pathogenesis in ALS/dementia. Here we show that mutations in UBQLN2, which encodes the ubiquitin-like protein ubiquilin 2, cause dominantly inherited, chromosome-X-linked ALS and ALS/dementia. We describe novel ubiquilin 2 pathology in the spinal cords of ALS cases and in the brains of ALS/dementia cases with or without UBQLN2 mutations. Ubiquilin 2 is a member of the ubiquilin family, which regulates the degradation of ubiquitinated proteins. Functional analysis showed that mutations in UBQLN2 lead to an impairment of protein degradation. Therefore, our findings link abnormalities in ubiquilin 2 to defects in the protein degradation pathway, abnormal protein aggregation and neurodegeneration, indicating a common pathogenic mechanism that can be exploited for therapeutic intervention.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Mutations of UBQLN2 in patients with ALS and ALS/dementia.
Figure 2: Ubiquilin-2-immunoreactive inclusions in the spinal cord and hippocampus.
Figure 3: Co-localization of ubiquilin 2 with ALS- and dementia-linked TDP43.
Figure 4: Mutations in ubiquilin 2 lead to ubiquitin-mediated impairment of proteasomal degradation.


  1. Deng, H. X. et al. Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase. Science 261, 1047–1051 (1993)

    Article  ADS  CAS  Google Scholar 

  2. Rosen, D. R. et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362, 59–62 (1993)

    Article  ADS  CAS  Google Scholar 

  3. Kabashi, E. et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nature Genet. 40, 572–574 (2008)

    Article  CAS  Google Scholar 

  4. Sreedharan, J. et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 319, 1668–1672 (2008)

    Article  ADS  CAS  Google Scholar 

  5. Kwiatkowski, T. J., Jr et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 323, 1205–1208 (2009)

    Article  ADS  CAS  Google Scholar 

  6. Vance, C. et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 323, 1208–1211 (2009)

    Article  ADS  CAS  Google Scholar 

  7. Chen, Y. Z. et al. DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). Am. J. Hum. Genet. 74, 1128–1135 (2004)

    Article  CAS  Google Scholar 

  8. Greenway, M. J. et al. ANG mutations segregate with familial and ‘sporadic’ amyotrophic lateral sclerosis. Nature Genet. 38, 411–413 (2006)

    Article  CAS  Google Scholar 

  9. Nishimura, A. L. et al. A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. Am. J. Hum. Genet. 75, 822–831 (2004)

    Article  CAS  Google Scholar 

  10. Yang, Y. et al. The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nature Genet. 29, 160–165 (2001)

    Article  CAS  Google Scholar 

  11. Chow, C. Y. et al. Deleterious variants of FIG4, a phosphoinositide phosphatase, in patients with ALS. Am. J. Hum. Genet. 84, 85–88 (2009)

    Article  CAS  Google Scholar 

  12. Maruyama, H. et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature 465, 223–226 (2010)

    Article  ADS  CAS  Google Scholar 

  13. Ticozzi, N. et al. Paraoxonase gene mutations in amyotrophic lateral sclerosis. Ann. Neurol. 68, 102–107 (2010)

    Article  CAS  Google Scholar 

  14. Mitchell, J. et al. Familial amyotrophic lateral sclerosis is associated with a mutation in D-amino acid oxidase. Proc. Natl Acad. Sci. USA 107, 7556–7561 (2010)

    Article  ADS  CAS  Google Scholar 

  15. Johnson, J. O. et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron 68, 857–864 (2010)

    Article  CAS  Google Scholar 

  16. Lansbury, P. T. & Lashuel, H. A. A century-old debate on protein aggregation and neurodegeneration enters the clinic. Nature 443, 774–779 (2006)

    Article  ADS  CAS  Google Scholar 

  17. Deng, H. X. et al. FUS-immunoreactive inclusions are a common feature in sporadic and non-SOD1 familial amyotrophic lateral sclerosis. Ann. Neurol. 67, 739–748 (2010)

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Neumann, M. et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130–133 (2006)

    Article  ADS  CAS  Google Scholar 

  19. Shibata, N. et al. Intense superoxide dismutase-1 immunoreactivity in intracytoplasmic hyaline inclusions of familial amyotrophic lateral sclerosis with posterior column involvement. J. Neuropathol. Exp. Neurol. 55, 481–490 (1996)

    Article  CAS  Google Scholar 

  20. Mackenzie, I. R. et al. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann. Neurol. 61, 427–434 (2007)

    Article  CAS  Google Scholar 

  21. Neumann, M. et al. Frontotemporal lobar degeneration with FUS pathology. Brain 132, 2922–2931 (2009)

    Article  Google Scholar 

  22. Urwin, H. et al. FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathol. 120, 33–41 (2010)

    Article  Google Scholar 

  23. Nonaka, T., Kametani, F., Arai, T., Akiyama, H. & Hasegawa, M. Truncation and pathogenic mutations facilitate the formation of intracellular aggregates of TDP-43. Hum. Mol. Genet. 18, 3353–3364 (2009)

    Article  CAS  Google Scholar 

  24. Ko, H. S., Uehara, T., Tsuruma, K. & Nomura, Y. Ubiquilin interacts with ubiquitylated proteins and proteasome through its ubiquitin-associated and ubiquitin-like domains. FEBS Lett. 566, 110–114 (2004)

    Article  Google Scholar 

  25. Dantuma, N. P., Lindsten, K., Glas, R., Jellne, M. & Masucci, M. G. Short-lived green fluorescent proteins for quantifying ubiquitin/proteasome-dependent proteolysis in living cells. Nature Biotechnol. 18, 538–543 (2000)

    Article  CAS  Google Scholar 

  26. Kay, B. K., Williamson, M. P. & Sudol, M. The importance of being proline: the interaction of proline-rich motifs in signaling proteins with their cognate domains. FASEB J. 14, 231–241 (2000)

    Article  CAS  Google Scholar 

  27. Aitio, O. et al. Recognition of tandem PxxP motifs as a unique Src homology 3-binding mode triggers pathogen-driven actin assembly. Proc. Natl Acad. Sci. USA 107, 21743–21748 (2010)

    Article  ADS  CAS  Google Scholar 

  28. Haapasalo, A. et al. Emerging role of Alzheimer’s disease-associated ubiquilin-1 in protein aggregation. Biochem. Soc. Trans. 38, 150–155 (2010)

    Article  CAS  Google Scholar 

  29. Kim, S. H. et al. Potentiation of amyotrophic lateral sclerosis (ALS)-associated TDP-43 aggregation by the proteasome-targeting factor, ubiquilin 1. J. Biol. Chem. 284, 8083–8092 (2009)

    Article  CAS  Google Scholar 

  30. Aguzzi, A. & O'Connor, T. Protein aggregation diseases: pathogenicity and therapeutic perspectives. Nature Rev. Drug Discov. 9, 237–248 (2010)

    Article  CAS  Google Scholar 

  31. Brooks, B. R., Miller, R. G., Swash, M. & Munsat, T. L. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 1, 293–299 (2000)

    Article  CAS  Google Scholar 

  32. Neary, D. et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 51, 1546–1554 (1998)

    Article  CAS  Google Scholar 

  33. Cairns, N. J. et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the consortium for frontotemporal lobar degeneration. Acta Neuropathol. 114, 5–22 (2007)

    Article  Google Scholar 

  34. Mackenzie, I. R. et al. Heterogeneity of ubiquitin pathology in frontotemporal lobar degeneration: classification and relation to clinical phenotype. Acta Neuropathol. 112, 539–549 (2006)

    Article  Google Scholar 

  35. Deng, H. X. et al. Conversion to the amyotrophic lateral sclerosis phenotype is associated with intermolecular linked insoluble aggregates of SOD1 in mitochondria. Proc. Natl Acad. Sci. USA 103, 7142–7147 (2006)

    Article  ADS  CAS  Google Scholar 

  36. Fecto, F. et al. Mutant TRPV4-mediated toxicity is linked to increased constitutive function in axonal neuropathies. J. Biol. Chem. 286, 17281–17291 (2011)

    Article  CAS  Google Scholar 

Download references


This study was supported by the National Institute of Neurological Disorders and Stroke (NS050641), the Les Turner ALS Foundation, the Vena E. Schaff ALS Research Fund, the Harold Post Research Professorship, the Herbert and Florence C. Wenske Foundation, the David C. Asselin MD Memorial Fund, the Help America Foundation and the Les Turner ALS Foundation/Herbert C. Wenske Foundation Professorship. F.F. has support from NIH (T32 AG20506). K.A. is a postdoctoral fellow of the Blazeman Foundation for ALS. G.H.G. received travel funds from MND Scotland. We thank N. Dantuma for the UPS reporter plasmid (through Addgene) and the staff of the Northwestern University Robert H. Lurie Comprehensive Cancer Center flow cytometry core facility for technical assistance. Imaging work was performed at the Northwestern University Cell Imaging Facility, supported by NCI CCSG P30 CA060553 awarded to the Robert H Lurie Comprehensive Cancer Center.

Author information

Authors and Affiliations



T.S. conceived and supervised this project. W.C., S.-T.H., Y.Y., H.J., M.H., H.-X.D. and T.S. did the sequencing analysis. S.T.H., E.R., J.L.H., M.P.-V. and T.S. performed linkage analysis. K.M.B., G.H.G., F.F., G.H.J., H.Z., E.H.B., K.A., E.M., H.-X.D. and T.S. performed immunohistochemical, confocal and pathological analysis. F.F., Y.S. and H.-X.D. performed functional analysis. N.S., S.D. and T.S. collected family information and coordinated this study. K.M.B., G.H.J., B.R.B., R.L.S. and T.S. did clinical studies. H.-X.D. and T.S. analysed the data and wrote the paper.

Corresponding author

Correspondence to Teepu Siddique.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Information

The file contains Supplementary Figures 1-18 with legends, Supplementary Tables 1-2 and Supplementary Case Notes. (PDF 2329 kb)

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Deng, HX., Chen, W., Hong, ST. et al. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature 477, 211–215 (2011).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing